戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eutrophils in the dermis in a mouse model of bubonic plague.
2 es, ranging from food-borne illnesses to the bubonic plague.
3 significantly attenuated in a mouse model of bubonic plague.
4 nduce the invasive infection associated with bubonic plague.
5 increased virulence and the emergence of the bubonic plague.
6 ory of gravity whilst quarantined during the bubonic plague.
7 contributes to disease in the mouse model of bubonic plague.
8 play an important role in the progression of bubonic plague.
9 el; however, it was attenuated in developing bubonic plague.
10 med to be important for the establishment of bubonic plague.
11 mination during pneumonic plague than during bubonic plague.
12 imic transmission by fleabite, leads only to bubonic plague.
13  rat closely resembled descriptions of human bubonic plague.
14  been proposed to provide protection against bubonic plague.
15 hese MPs significantly increased survival of bubonic plague.
16 se that is an essential virulence factor for bubonic plague.
17 s ranging from gastrointestinal syndromes to Bubonic Plague.
18 o its current frequency can be attributed to bubonic plague.
19 s ranging from gastrointestinal syndromes to bubonic plague.
20 ifferent stages of the infectious process of bubonic plague.
21 f infection that mimics flea transmission of bubonic plague.
22 r of Yersinia pestis, the causative agent of bubonic plague.
23  with antibody therapy in the mouse model of bubonic plague.
24 mbination for the treatment of patients with bubonic plague.
25                       Yersinia pestis causes bubonic plague, a fulminant disease where host immune re
26 ions to study bacterial dissemination during bubonic plague and compare this model with an s.c. inocu
27 antibody responses that protect mice against bubonic plague and pneumonic plague, suggesting that rV1
28    Yersinia pestis is the causative agent of bubonic plague and possesses a set of plasmid-encoded, s
29 tigations into the molecular pathogenesis of bubonic plague and the immune response to Y. pestis at d
30 f new vaccines to prevent naturally acquired bubonic plague and to study events at the vector-host in
31  exhibited an exceptional capacity to resist bubonic plague and used it to identify immune mechanisms
32 nt resulted in an atypical, subacute form of bubonic plague associated with extensive recruitment of
33 e clusters are present in the genomes of the bubonic plague bacillus Yersinia pestis and the human an
34                          Yersina pestis, the bubonic plague bacterium, is coated with a polymeric pro
35  superfamily, is an effector produced by the bubonic plague bacterium, Yersinia pestis, that is essen
36                Yersinia pestis, the cause of bubonic plague, blocks feeding by its vector, the flea.
37  cells and a large decrease in virulence for bubonic plague but not for pneumonic plague in mice.
38 decreases the mortality of mice in models of bubonic plague but not in the pneumonic and septicemic f
39 , spatial metapopulation model, we show that bubonic plague can persist in relatively small rodent po
40  use provides significant protection against bubonic plague caused by an F1- strain (C12) or against
41                          In a mouse model of bubonic plague, CCR2 also was shown to be required for D
42 in combination, conferred protection against bubonic plague challenge in mice.
43                       Yersinia pestis causes bubonic plague, characterized by an enlarged, painful ly
44 ia pestis is transmitted by fleas and causes bubonic plague, characterized by severe local lymphadeni
45 the more biologically relevant i.d. model of bubonic plague differs significantly from the s.c. model
46 ) in Madagascar who had clinically suspected bubonic plague during 2020-2024.
47 gory BSL 3 and 4 pathogens, such as anthrax, bubonic plague, Ebola and Marburg fever.
48                Yersinia pestis, the agent of bubonic plague, evolved from the enteric pathogen Yersin
49                             A mouse model of bubonic plague failed to show a significant role for the
50 le of Yersinia pestis YopJ in a rat model of bubonic plague following intradermal infection with a fu
51 uring infection, but the role of YopJ during bubonic plague has not been completely established.
52 (Ab) can provide complete protection against bubonic plague in animal models, the mechanisms responsi
53 ull pathogenic ability in both pneumonic and bubonic plague in C57BL/6J mice.
54                                              Bubonic plague in humans follows transmission by infecte
55 ntly caught ill-prepared societies off-guard-Bubonic plague in medieval times, AIDS in the 1980s, and
56 ugh flea-borne transmission usually leads to bubonic plague in mice, it can also lead to primary sept
57 adermal model, suggesting a role for YopM in bubonic plague, in which acute inflammation occurs soon
58 in macrophages and for virulence in a murine bubonic plague infection assay.
59           Here, the historical background of bubonic plague is briefly described and recent studies i
60 ional human-disease models, and propose that bubonic plague is driven by the dynamics of the disease
61                              The hallmark of bubonic plague is the presence of grotesquely swollen ly
62                                              Bubonic plague is transmitted by fleas whose feeding is
63                                              Bubonic plague is transmitted by fleas whose feeding is
64                                              Bubonic plague is transmitted to mammals, including huma
65                                              Bubonic plague is widely regarded as a disease of mainly
66 s of Yersinia pestis, the causative agent of bubonic plague, is the yersiniabactin (Ybt) siderophore-
67 lence of Yersinia pestis, causative agent of bubonic plague, is the yersiniabactin (Ybt) siderophore-
68                Yersinia pestis, the cause of bubonic plague, is transmitted by the bites of infected
69                                          For bubonic plague, mice dosed with Salmonella-(F1+V)Ags and
70 Brown Norway rat was recently described as a bubonic plague model that closely mimics human disease.
71 tially avirulent via subcutaneous injection (bubonic plague model).
72 tive to the Yfe(+) Feo(+) parent strain in a bubonic plague model.
73 ersinia pestis, the agent of the Black Death/bubonic plague of the 14th century.
74                                              Bubonic plague, one of history's deadliest infections, i
75 on may have been selectively advantageous in bubonic plague, owing to rodent fragmentation after pand
76 pestis against complement-mediated lysis, on bubonic plague pathogenesis in mice and rats.
77 ults indicate that YopJ is not essential for bubonic plague pathogenesis, even after peripheral inocu
78                                              Bubonic plague results when Yersinia pestis is deposited
79 large-scale food-borne illnesses, dysentery, bubonic plague, secondary hospital infections, and sexua
80      Yersinia pestis, the causative agent of bubonic plague, secretes a eukaryotic-like protein tyros
81 ons, we analyze the full ecoepidemiological (bubonic) plague system.
82 indicating a more important role for RovA in bubonic plague than pneumonic plague or systemic infecti
83 past because it provided protection against (bubonic) plague; the mutation, called CCR5Delta32, is ch
84 ases explored include tuberculosis, leprosy, bubonic plague, typhoid, syphilis, endemic and epidemic
85                      We developed a model of bubonic plague using the inbred Brown Norway strain of R
86    The Y. pestis Ail protein is an important bubonic plague virulence factor that inhibits the innate
87                         Using a rat model of bubonic plague, we examined lymph node histopathology, t
88 rwent screening; 450 patients with suspected bubonic plague were enrolled and underwent randomization
89  septicemic plague at low incidence, but not bubonic plague, when transmitted by fleas.
90  and Yersinia pestis, the causative agent of bubonic plague, which has a flea vector.
91 on at 8 LD50 when tested in a mouse model of bubonic plague, with infection by 10/20 of the aforement
92  LcrV in the passive transfer of immunity to bubonic plague, with multiple neutralizing epitopes in L
93 y to control malaria, typhus, body lice, and bubonic plague worldwide, until countries began restrict
94 onsiderable historical interest - pre-modern bubonic plague (Yersinia pestis), smallpox (Variola viru
95 a from the catastrophic European Black Death/bubonic plague (Yersinia pestis).
96                       The etiologic agent of bubonic plague, Yersinia pestis, senses self-produced, s